Loading...
•
Dec 31, 2023
Mural Oncology Q4 2023 Earnings Report
Mural Oncology announced its financial results for Q4 2023 and provided a business update.
Key Takeaways
Mural Oncology reported a net loss of $59.5 million for the fourth quarter of 2023. As of December 31, 2023, cash and cash equivalents were $270.9 million. The company expects its cash resources to fund operations into the fourth quarter of 2025.
Mural Oncology became an independent company in November 2023.
The company plans to evaluate the LFIV nemvaleukin dosing regimen in cohort 3 of ARTISTRY-6.
Enrollment is ongoing for ARTISTRY-6 and ARTISTRY-7.
Mural Oncology intends to nominate development candidates for IL-18 and IL-12 therapies in 2024.
Mural Oncology
Mural Oncology
Forward Guidance
Mural Oncology expects its cash resources to fund its operations into the fourth quarter 2025 and anticipates reporting lower operating expenses in the quarters going forward.